Immatics (IMTX) Investor Presentation summary

PRAME as a cancer target

• PRAME is highly expressed in over 50 cancer types, with prevalence ≥95% in several, including cutaneous melanoma, uterine carcinoma, and synovial sarcoma.

• PRAME is an intracellular protein presented on tumor cells by HLA molecules, making it accessible to engineered TCR therapies.

• High PRAME expression is linked to poor prognosis and tumor survival mechanisms.

PRAME franchise and clinical pipeline

• The PRAME franchise includes three main clinical candidates: anzu-cel (IMA203), IMA203CD8, and IMA402, covering cell therapy and bispecific modalities.

• Anzu-cel targets advanced melanoma and uveal melanoma, with market entry planned for 2027.

• IMA203CD8 aims to expand to all advanced PRAME cancers, while IMA402 targets earlier-line cancers and combination regimens.

Clinical data: anzu-cel (IMA203) in melanoma

• Confirmed objective response rate (CORR) of 56% in heavily pretreated metastatic melanoma patients, with deep responses in 42%.

• Median duration of response (mDOR) is 12.1 months, with ongoing responses up to 2.5+ years.

• Median progression-free survival (mPFS) is 6.1 months, and median overall survival (mOS) is 15.9 months.

• Tolerability profile is favorable, with most adverse events being manageable cytopenias and low rates of severe neurotoxicity.